Join our daily newsletter At The Bell to receive exclusive market insights
- The Calmer Co International (ASX:CCO) supplies its Kavaton extract to leading US practitioner supplements brand, Metagenics
- Metagenics is using the extract for a new product, Metasleep, which aids sleep, lifestyle and good health and it now has exclusive rights to Kavaton in the US
- The Calmer Co distributes the extract in partnership with Network Nutrition, to the US$4 billion natural products market
- Metagenics Network Nutrition Brand Director Ryan Gorman says the launch is a positive step forward for the company
- CCO shares last traded at 0.6 cents
The Calmer Co International (ASX:CCO) has supplied its Kavaton extract to leading US practitioner supplements brand, Metagenics, for the launch of its latest product, MetaSleep.
Metagenics markets personalised lifestyle medicines in the US and sells professional-grade supplements to support good health.
MetaSleep is a proprietary formula containing both Melatonin and Kavaton, and The Calmer Co distributed the extract in partnership with Network Nutrition.
“This launch has been the culmination of more than a year of business development work with the Network Nutrition team,” CCO CEO Anthony Noble said.
“Having Kavaton presented in a blue-chip brand portfolio such as Metagenics is a huge win for the partnership.”
The US practitioner nutraceutical market is worth US$4 billion in sales and is one of the fastest-growing segments in the natural products industry, and Metagenics now has exclusive rights to Kavaton in the USA.
Metagenics Network Nutrition Brand Director Ryan Gorman said the launch was a positive step forward for the company.
“…We’re encouraged by the support of such a prominent and well-established global brand, throwing their weight behind the virtues of Kavaton,” he said.
CCO shares last traded at 0.6 cents.
